Panacur AquaSol

Country: European Union

Language: Bulgarian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

фенбендазол

Available from:

Intervet International BV

ATC code:

QP52AC13

INN (International Name):

fenbendazole

Therapeutic group:

Pigs; Chicken

Therapeutic area:

Антгельминтики, , Бензимидазолы и сродни вещества, фенбендазола

Therapeutic indications:

За лечение на стомашно-чревни нематоди от свине, заразени с:аскарида АЧС (възрастен, червата и миграция-ларва хранително стадии);Oesophagostomum). (възрастни етап);власоглавы suis (възрастни етап). За лечение на стомашно-чревни нематодозах пилета, заразени с:Ascaridia Galli л (L5 и възрастни);Heterakis gallinarum (Л5 и възрастни);Capillaria). (Л5 и възрастни).

Product summary:

Revision: 6

Authorization status:

упълномощен

Authorization date:

2011-12-09

Patient Information leaflet

                                B. ЛИСТОВКА
15
ЛИСТОВКА:
PANACUR AQUASOL
200 MG/ML, СУСПЕНЗИЯ ЗА ПРИЛОЖЕНИЕ, ВЪВ
ВОДАТА ЗА ПИЕНЕ, ЗА ПРАСЕТА И ПИЛЕТА
1.
ИМЕ И ПОСТОЯНEН АДРЕС НА ПРИТЕЖАТЕЛЯ
НА ЛИЦЕНЗА ЗА УПОТРЕБА
И НА ПРОИЗВОДИТЕЛЯ, АКО ТЕ СА РАЗЛИЧНИ
Притежател на лиценза за употреба
:
Intervet International BV
Wim de Körverstraat 35
5831 AN Boxmeer
The Netherlands
Производител, отговорен за
освобождаване на партидата
:
Intervet Productions SA
Rue de Lyons
27460 Igoville
France
2.
НАИМЕНОВАНИЕ НА
ВЕТЕРИНАРНОМЕДИЦИНСКИЯ ПРОДУКТ
Panacur AquaSol, 200 mg/ml, суспензия за
приложение, във водата за пиене, за
прасета и пилета.
3.
СЪДЪРЖАНИЕ НА АКТИВНАТА СУБСТАНЦИЯ И
ЕКСЦИПИЕНТИТЕ
Ветеринарномедицинският продукт е
перорална суспензия за приложение
чрез вода за пиене с
бял до светлокремав цвят, съдържаща 200
mg/ml fenbendazole и 20 mg/ml benzyl alcohol (Е1519).
4.
ТЕРАПЕВТИЧНИ ПОКАЗАНИЯ
Прасета:
За лечение и контрол на
гастроинтестинални нематоди при
прасета, опаразитени с:
-
_Ascaris suum_
(възрастни, интестинални и мигриращи
ларвни форми)
_ _
_- _
_Oesophagostomum_
spp (възрастни форми)
-
_Trichuris suis (възрастни форми) _
Пилета:
Лечение на гастроинтестинални
нематоди при пилета, опаразитени с:
_-_
_ _
_Ascaridia galli_
(L5 и възрастни форми)
_-_
_ _
_Heterakis gallinarum_
(L5 и възрастни форми)
_-_
_ _
_Capillaria_
spp. (L5 и 
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                _ _
_ _
ПРИЛОЖЕНИЕ I
КРАТКА ХАРАКТЕРИСТИКА НА ПРОДУКТА
1
1.
НАИМЕНОВАНИЕ НА
ВЕТЕРИНАРНОМЕДИЦИНСКИЯ ПРОДУКТ
Panacur AquaSol 200 mg/ml, суспензия за
приложение във водата за пиене, за
прасета и пилета.
2.
КАЧЕСТВЕН И КОЛИЧЕСТВЕН СЪСТАВ
1 ml съдържа:
АКТИВНА СУБСТАНЦИЯ:
Fenbendazole
200 mg
ЕКСЦИПИЕНТИ:
Benzyl alcohol (E1519)
20 mg
За пълния списък на ексципиентите, виж
т.6.1.
3.
ФАРМАЦЕВТИЧНА ФОРМА
Суспензия за приложение във вода за
пиене с бял до светлокремав цвят.
Частиците на суспензията са с размер
по-малък от 1 микрон.
4.
КЛИНИЧНИ ДАННИ
4.1
ВИДОВЕ ЖИВОТНИ, ЗА КОИТО Е
ПРЕДНАЗНАЧЕН ВМП
Прасета и пилета.
4.2
ТЕРАПЕВТИЧНИ ПОКАЗАНИЯ, ОПРЕДЕЛЕНИ ЗА
ОТДЕЛНИТЕ ВИДОВЕ ЖИВОТНИ
Прасета:
Лечение и контрол на
гастроинтестинални нематоди при
прасета, опаразитени с:
_-_
_ _
_Ascaris suum_
(възрастни, интестинални и мигриращи
ларвни форми)
_-_
_ _
_Oesophagostomum_
spp (възрастни форми)
_-_
_ _
_Trichuris suis_
(възрастни форми)
Пилета:
Лечение на гастроинтестинални
нематоди при пилета, опаразитени с:
_-_
_ _
_Ascaridia galli_
(L5 и възрастни форми)
_-_
_ _
_Heterakis gallinarum_
(L5 и възрастни форми)
_-_
_ _
_Capillaria _
spp.( L5 и възрастни форми)
4.3
ПРОТИВОПОКАЗАНИЯ
Няма
4.4
СПЕЦИАЛНИ ПРЕДПАЗНИ МЕРКИ ЗА ВСЕКИ
ВИД ЖИВОТНИ, ЗА КОИТО Е ПРЕДНАЗ
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Spanish 26-04-2018
Public Assessment Report Public Assessment Report Spanish 26-04-2018
Patient Information leaflet Patient Information leaflet Czech 26-04-2018
Public Assessment Report Public Assessment Report Czech 26-04-2018
Patient Information leaflet Patient Information leaflet Danish 26-04-2018
Public Assessment Report Public Assessment Report Danish 26-04-2018
Patient Information leaflet Patient Information leaflet German 26-04-2018
Public Assessment Report Public Assessment Report German 26-04-2018
Patient Information leaflet Patient Information leaflet Estonian 26-04-2018
Public Assessment Report Public Assessment Report Estonian 26-04-2018
Patient Information leaflet Patient Information leaflet Greek 26-04-2018
Public Assessment Report Public Assessment Report Greek 26-04-2018
Patient Information leaflet Patient Information leaflet English 26-04-2018
Public Assessment Report Public Assessment Report English 26-04-2018
Patient Information leaflet Patient Information leaflet French 26-04-2018
Public Assessment Report Public Assessment Report French 26-04-2018
Patient Information leaflet Patient Information leaflet Italian 26-04-2018
Public Assessment Report Public Assessment Report Italian 26-04-2018
Patient Information leaflet Patient Information leaflet Latvian 26-04-2018
Public Assessment Report Public Assessment Report Latvian 26-04-2018
Patient Information leaflet Patient Information leaflet Lithuanian 26-04-2018
Summary of Product characteristics Summary of Product characteristics Lithuanian 26-04-2018
Public Assessment Report Public Assessment Report Lithuanian 26-04-2018
Patient Information leaflet Patient Information leaflet Hungarian 26-04-2018
Summary of Product characteristics Summary of Product characteristics Hungarian 26-04-2018
Public Assessment Report Public Assessment Report Hungarian 26-04-2018
Patient Information leaflet Patient Information leaflet Maltese 26-04-2018
Public Assessment Report Public Assessment Report Maltese 26-04-2018
Patient Information leaflet Patient Information leaflet Dutch 26-04-2018
Public Assessment Report Public Assessment Report Dutch 26-04-2018
Patient Information leaflet Patient Information leaflet Polish 26-04-2018
Public Assessment Report Public Assessment Report Polish 26-04-2018
Patient Information leaflet Patient Information leaflet Portuguese 26-04-2018
Summary of Product characteristics Summary of Product characteristics Portuguese 26-04-2018
Public Assessment Report Public Assessment Report Portuguese 26-04-2018
Patient Information leaflet Patient Information leaflet Romanian 26-04-2018
Public Assessment Report Public Assessment Report Romanian 26-04-2018
Patient Information leaflet Patient Information leaflet Slovak 26-04-2018
Public Assessment Report Public Assessment Report Slovak 26-04-2018
Patient Information leaflet Patient Information leaflet Slovenian 26-04-2018
Summary of Product characteristics Summary of Product characteristics Slovenian 26-04-2018
Public Assessment Report Public Assessment Report Slovenian 26-04-2018
Patient Information leaflet Patient Information leaflet Finnish 26-04-2018
Public Assessment Report Public Assessment Report Finnish 26-04-2018
Patient Information leaflet Patient Information leaflet Swedish 26-04-2018
Public Assessment Report Public Assessment Report Swedish 26-04-2018
Patient Information leaflet Patient Information leaflet Norwegian 26-04-2018
Summary of Product characteristics Summary of Product characteristics Norwegian 26-04-2018
Patient Information leaflet Patient Information leaflet Icelandic 26-04-2018
Summary of Product characteristics Summary of Product characteristics Icelandic 26-04-2018
Patient Information leaflet Patient Information leaflet Croatian 26-04-2018
Public Assessment Report Public Assessment Report Croatian 26-04-2018